Amir A.JazaeriMDFACS, FACOG
Obstetrics & Gynecology • Houston, TXGynecologic Oncology
Vice Chair for Clinical Research and Director of the Gynecologic Cancer Immunotherapy Program Department of Gynecologic Oncology & Reproductive Medicine University of Texas MD Anderson Cancer Center Vice chair for clinical research
Dr. Jazaeri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2000 - 2004
University of Virginia Medical CenterResidency, Obstetrics and Gynecology, 1996 - 2000
University of Virginia School of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2002 - 2024
OK State Medical License 2020 - 2021
VA State Medical License 1998 - 2018- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 2004 Jun 01
- Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2006 Apr 13
- Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery Start of enrollment: 2016 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.Anne Knisely, Emily Hinchcliff, Bryan Fellman, Ann Mosley, Kathryn Lito, Sara Hull, Shannon N Westin, Anil K Sood, Kathleen M Schmeler, Jolyn S Taylor, Steven Y Huang,...> ;Med. 2024 Apr 12
- 1 citationsEfficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.Amaria, R., Knisely, A., Vining, D., Kopetz, S., Overman, M., Javle, M., Antonoff, M., Tzeng, C., Wolff, R., Pant, S., Lito, K., Rangel, K., Fellman, B., Yuan, Y., Lu,...> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
- EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.Vo, D., Liu, Y., Sood, A., Rezvani, K., Liu, J., Jazaeri, A.> ;Cancer Biomarkers. 2023 Dec 28
- Join now to see all
Lectures
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical c...2019 ASCO Annual Meeting - 6/1/2019
- A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or pe...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Professional Memberships
- Member
- Fellow
- Member
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
